Although the initiating step of mesoderm formation is well characterized, the subsequent steps that promote for cardiac lineages are poorly understood and limit the yield of cardiomyocytes.
H eart disease often leads to cardiomyocyte death and pathological remodeling, and the only replacement option is heart transplantation, but its clinical complexity and the limited number of donors have prompted research into stem cell-based alternatives. Stem cell-based approaches include both cell transplantation and mobilization of an endogenous stem and progenitor pool, which show promise for therapeutic regeneration. 1 Development of stem cellbased replacement therapies, however, is limited by incomplete understanding of the factors that drive differentiation of cardiomyocytes from either human embryonic stem cells (hESCs) or endogenous cardiac stem and progenitor cells. Therefore, we sought to develop high-throughput screens for simultaneous testing of small molecules for cardiogenic potential in order to identify cellular signals that are required or need to be inhibited at different stages of cardiac development. 2 Moreover, such a chemical biology approach would generate small-molecule tools to improve the yield in hESC differentiation protocols and could even result in drug leads for cardiac regeneration should they target hESC-derived progenitors that resemble adult cardiac progenitor cells. Here, we describe the development and implementation of an hESC-based assay that probes the signals that drive the conversion of platelet-derived growth factor receptor-␣ (PDGFR-␣) ϩ -mesoderm posterior 1 homolog (MESP1) ϩ cardiogenic cells to cardiomyo-cytes, as well as one of the hits that arose from screening pathway modulator libraries.
Methods
MYH6-mCherry hESC were propagated as described previously 3 and were differentiated with growth factors as outlined in Figure 1A . For high-content screening (HCS), day 4 embryoid bodies (EBs) were dissociated and plated in the presence of small molecules. For analysis, red fluorescence from the cardiac-specific MYH6 reporter was imaged with a high-throughput microscope and was quantified with an image analysis software package.
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Results
To develop an HCS assay for small molecules that drive mesoderm to differentiate into cardiomyocytes in hESCs, we first profiled cardiac marker expression during differentiation in EBs ( Figure 1A line). Because mesoderm induction appeared to be maximal at day 4, we further characterized the day 4 population for the early cardiac markers MESP1 and PDGFR-␣ ( Figure 1B ). 5 Because this population appeared to be highly enriched for both markers, we developed an HCS assay that would probe these cells and determine what signals would drive differentiation toward cardiomyocytes ( Figure 1A , lower half). HCS assays are image-based and have better dynamic range and sensitivity than traditional plate-reader-based assays. Day 4 EBs were collected and dispersed into 384-well plates and subsequently exposed to 3 concentrations (0.3, 1, and 3 mol/L) of 2 small collections of well-characterized pathway modulators, namely, approximately 244 protein kinase inhibitors (InhibitorSelect; EMD Millipore, Billerica, MA) and 305 pathway agonists and antagonists (StemSelect; EMD Chemicals). In the InhibitorSelect collection, no compound induced cardiogenesis ( Figure 1C ), whereas in the StemSelect collection, 1 extremely potent hit was identified ( Figure 1D ). The hit IWR-1, a recently published inhibitor of the canonical Wnt signaling response (IWR), 6 induced beating foci from monolayer cultures, whereas none were observed in dimethyl sulfoxide conditions ( Figure 1E ; Online Movies I and II). Inhibitors of endothelial growth factor, vascular epidermal growth factor, transforming growth factor-␤, insulin, and Sonic hedgehog signaling did not result in increased cardiogenesis, which suggests that Wnt inhibition alone is sufficient for cardiac induction (Online Table I ). Moreover, agonists of the Wnt, vascular endothelial growth factor, and Sonic hedgehog pathways failed to promote cardiac fate (Online Table I ).
Further characterization revealed that maximal cardiac induction by IWR occurs when IWR is added from day 4 to day 5, with cardiac induction levels decreasing as the treatment window is shifted up toward day 10 of differentiation (Figure 2A ). The EC 50 to induce cardiogenesis at the day 4 time window was 2241 nmol/L ( Figure 2B ). Flow cytometry analysis demonstrated that IWR yielded up to 30% cardiomyocytes, a 200-fold increase over vehicle-treated cultures ( Figure 2C ). Reverse transcription quantitative polymerase chain reaction analysis was performed to study the effect of IWR on mesoderm, cardiac progenitors, and mesoderm derivatives such as cardiomyocytes, endothelial cells, and smooth muscle ( Figure 2D ). The mesoderm-specific gene T/BRACHYURY had a downward tendency as soon as 24 hours after IWR exposure, although this was not statistically significant on most days ( Figure 2D ). The earliest markers of cardiac fate, MESP1 and kinase insert domain receptor, were not affected in the first few days after IWR treatment, which suggests that IWR drives MESP1 ϩ , kinase insert domain receptor ϩ cardiac mesoderm cells toward cardiomyocytes ( Figure 2D ). MEF2C and NKX2.5, 2 cardiac transcription factors, as well as the cardiomyocyte structural genes MYH6, ACTN2, and TNNT2, were increased dramatically by IWR ( Figure 2D ). Further characterization of other mesodermal lineages revealed smooth muscle lineages were not increased (ACTA2 and TGLN) and endothelial cell markers (CD31 and kinase insert domain receptor) even decreased. Flow cytometry confirmed a Ͼ50% reduction in CD31 ϩ cells (Online Figure II) .
We next questioned whether other inhibitors of the Wnt pathway were also able to induce cardiogenesis in this assay ( Figure 3A) . We tested 3 more small-molecule inhibitors of Wnt signaling: (1) the PORCN inhibitor IWP-3 (IWP) 6 ; (2) the more potent IWR-1 analog 53AH; and (3) the tankyrase inhibitor XAV939 (XAV), which is cardiogenic in mouse embryonic stem cells. 7 All 3 compounds promoted cardiogenesis, with 53AH having an EC 50 below the micromolar range ( Figure 3B ). Because EC 50 measurements are not indicative of the efficacy of each compound, we ran maximal effect doses of each compound, as well as the biological Wnt inhibitor DKK1 (Dickkopf-related protein 1), per comparison to evaluate their maximum efficacy in terms of cardiogenesis. IWR and its analog 53AH were the most efficacious, followed by IWP and XAV, and any of the small-molecule inhibitors were at least 40 times more effective in inducing cardiogenesis than DKK1, a purified recombinant Wnt inhibitor protein ( Figure 3C ).
Discussion
Definition of the pathways that control stem cell cardiogenesis is important to efficiently derive cardiomyocytes from human pluripotent stem cells and might be useful to mobilize endogenous cardiac stem cells. To discover new molecules and pathways that would direct cardiac differentiation and/or regeneration, we developed an hESC-based HCS assay that allows small-molecule screens in serum-free conditions, on a scale that has not been reported for any hESC-based assay. We prepared cardiogenic mesoderm (platelet-derived growth factor receptor␣ ϩ MESP1 ϩ ) cells in bulk EB culture ( Figure  1B ) 5 and dispersed and plated the cells in a monolayer with the intent of identifying small molecules that are able to replace the natural signals provided in the 3-dimensional EB, thus yielding insight into signals that direct mesodermal progenitors to form cardiomyocytes.
By screening approximately 550 pathway modulators, we identified a small-molecule inhibitor of the ␤-catenindependent canonical Wnt pathway. Although it was not entirely unexpected that a Wnt inhibitor would be identified as a cardiac inducer, given that the natural Wnt inhibitor DKK1 is capable of directing cardiogenesis in Xenopus 8 and hESCs, 5 the present study showed that Wnt inhibition was sufficient to drive the hESC-derived mesoderm to a cardiac fate in the absence of other signaling modulators, and no other inhibitors had comparable activity (Online Table I ). Moreover, Wnt inhibition drove cardiomyocytes specifically and did not increase other mesoderm lineages, which suggests that Wnt inhibition specifically drives a mesoderm progenitor toward cardiomyocytes ( Figures 2D and 2E) .
To further explore inhibition throughout the Wnt pathway, we evaluated structurally diverse Wnt inhibitors that target different cellular components of the pathway ( Figure 3D ). Importantly, all of the small molecules were much more cardiogenic than DKK1 ( Figure 3C ). The most interesting finding, however, was that IWP, an inhibitor that prevents cells from producing Wnt, was also potent, which revealed that endogenous Wnt activity must be blocked. This is an important finding, because it suggests not only that exogenously added factors are important for efficient differentiation but also that endogenous cellular signals may have to be modulated to control differentiation. Because these cultures are typically heterogeneous, further experimentation may unravel which cell type is, in this case, secreting inhibitory Wnts.
In summary, HCS of an hESC-based assay identified Wnt inhibition as critical for cardiogenesis. Active compounds function by blocking Wnt secretion and stabilize Axin to destabilize ␤-catenin. The present data further suggest that endogenous Wnt signals need to be inhibited to direct the formation of cardiomyocytes from a mesoderm progenitor.
